Physician profile
Jonathan P Oline
NPI 1699747485
$2,294.34
in general payments reported to CMS, 2019-2025
19 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $122 · 2023: $492 · 2024: $799 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.60 | 2023-2025 | Otezla, Evenity, Krystexxa |
| Lilly USA, LLC | $261.85 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $242.37 | 2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $128.56 | 2025 | Wegovy |
| Biocryst US Sales Co., LLC | $127.49 | 2024 | Orladeyo |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $124.59 | 2023 | Dvr Anatomic Kickstand |
| Phathom Pharmaceuticals, INC. | $121.53 | 2024 | Voquezna |
| Janssen Biotech, INC. | $120.80 | 2025 | Simponi Aria, Tremfya |
| Genzyme Corporation | $97.68 | 2024 | |
| Pfizer INC. | $96.62 | 2025 | |
| Boston Scientific Corporation | $85.14 | 2023 | Watchman Flx |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.68 | 2023 | |
| Ani Pharmaceuticals, INC. | $82.68 | 2025 | Purified Cortrophin Gel |
| Vertos Medical, INC. | $77.33 | 2023 | Mild Device Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $67.30 | 2024 | Idose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.04 | 2025 | Jardiance |
| Biogen, INC. | $22.95 | 2024 | Skyclarys |
| Abbvie INC. | $22.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Oline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.